Hemostasis and COVID-19Managing coagulation abnormalities in COVID-19 patients
Siemens Healthineers is supporting labs in the diagnosis, treatment, and management of coagulation abnormalities in COVID-19 patients.
For more than 40 years, Siemens Healthineers has been recognized as the global leader in hemostasis testing. We offer the broadest range of scalable hemostasis systems for low-, mid- and high-volume laboratories. Our comprehensive portfolio of coagulation assays supports physicians in making sound diagnostic and therapeutic decisions.
We’ve increased production of vital coagulation assays for quick, accurate identification and treatment of clotting abnormalities.
Our coagulation tests are playing an important role in the diagnosis, treatment, and management of coagulation abnormalities in COVID-19 patients. We’ve been working diligently to produce these assays at a higher volume than ever before.
We’ve changed our production model to ensure an increased output of reagents, while also putting appropriate safety measures in place which are intended to help protect our workers from exposure to COVID-19. We will continue these efforts so that we remain positioned to provide high-quality assays to meet the increased testing demand.
Early detection and treatment of coagulation abnormalities can save lives.
As part of our commitment to labs and clinicians in the fight against the pandemic, we aim to keep you informed on current coagulation testing and monitoring recommendations in COVID-19 patients. Read our eBook for an overview on:
- Thrombosis risk factors
- ISTH-recommended coagulation testing algorithm
- Leading recommendations for anticoagulation treatment
- Relevant parameters for patient monitoring